Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast

Sao Paulo Medical Journal

Volumn 124, Issue 3, 2006, Pages 121-124

  de Menezes, Marcus Vinicius Martins ^a   Cestari, Anna Leticia Oliveira ^a   Almeida, Orlando ^a   Alvarenga, Marcelo ^a   Pinto, Glauce Aparecida ^a   Gurgel, Maria Solete Costa ^a   de Souza, Gustavo Antônio ^a   Zeferino, Luis Carlos ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Breast neoplasms; Carcinoma; Ductal carcinoma in situ; Protein p53; Receptor erbB 2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53;

ARTICLE; BRAZIL; BREAST CARCINOMA; CANCER CELL; CANCER GRADING; CANCER INVASION; CARCINOGENESIS; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

EID: 33748860435     PISSN: 15163180     EISSN: 15163180     Source Type: Journal    
DOI: 10.1590/s1516-31802006000300002     Document Type: Article

References (24)

1. Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol. 2002;196(3):280-6.
2. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430-41.
3. Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol. 2000;9(1):14-9.
4. Mommers EC, Leonhart AM, Falix F, et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol. 2001;194(3):327-33.
5. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer. 2001;85(6):869-74.
6. Goldstein NS, Murphy T. Intraductal carcinoma associated with invasive carcinoma of the breast. A comparison of the two lesions with implications for intraductal carcinoma classification systems. Am J Clin Pathol. 1996;106(3):312-8.
7. Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer. 1997;80(9):1798-802.
8. Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991.
9. De Potter CR, Van Daelle S, Van de Vijver MJ, et al. The expression of the neu oncogne product in breast lesions and in normal fetal and adult human tissues. Histopathology. 1989;15(4):351-62.
10. Umekita Y, Takasaki T, Yoshida H. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study. Virchows Arch. 1994;424(5):491-4.
11. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23(9):974-9.
12. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68.
13. Aubele M, Werner M, Höfler H. Genetic alterations in presumptive precursor lesions of breast carcinomas. Anal Cell Pathol. 2002;24(2-3):69-76.
14. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8(1):47-61.
15. Coene ED, Schelfhout V, Winkler RA, et al. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Virchows Arch. 1997;430(5):365-72.
16. Heffelfinger SC, Yassin R, Miller MA, Lower EE. Cyclin D1, retinoblastoma, p53, and Her2/neu protein expression in preinvasive breast pathologies: correlation with vascularity. Pathobiology. 2000;68(3):129-36.
17. Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992;16(12):1133-43.
18. Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998; 34(6):791-808.
19. Warnberg F, Casalini P, Nordgren H, Bergkvist L, Holmberg L, Menard S. Ductal carcinoma in situ of the breast: a new phenotype classification system, and its relation to prognosis. Breast Cancer Res Treat. 2002;73(3):215-21.
20. Alexiev BA, Bassarova AV, Popovska SL, Popov AA, Christov CZ. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index. Gen Diagn Pathol. 1997;142(5-6):271-9.
21. Viacava P, Naccarato AG, Bevilacqua G. Different proliferative patterns characterize different preinvasive breast lesions. J Pathol. 1999;188(3):245-51.
22. Giardina C, Serio G, Lepore G, et al. Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study. J Exp Clin Cancer Res. 2003;22(2):279-88.
23. Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markets in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1(5):362-75.
24. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974-9.